Navigation Links
Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
Date:4/27/2011

SEATTLE, April 27, 2011 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Carlos V. Paya, MD, PhD, will join IDC as Chief Executive Officer and Board Director effective May 2, 2011, to lead IDC into its next stage of growth. Dr. Paya brings a successful track record and over 25 years of scientific, clinical and executive management experience to IDC.  

Current CEO and co-founder Steven Reed, PhD, will continue to serve on IDC's executive management team and Board of Directors and focus his efforts on scientific and strategic partnerships.  Dr. Reed remarked, "We are fortunate to have someone of Dr. Paya's caliber joining IDC.  We are confident that with his broad expertise, he will contribute to IDC's continued growth and success. Throughout his distinguished career, Dr. Paya has consistently demonstrated exceptional business and leadership acumen in a variety of management roles."

Bruce L.A. Carter, PhD, Chairman of IDC's Board of Directors stated, "Dr. Paya is an intelligent, independent thinker who's passionate about IDC's objective to discover and develop therapeutics that will protect and improve the quality of people's lives. I am excited to be working with him as IDC continues to progress."

"I am honored to join such an accomplished and recognized Board of Directors, executive team, and a first in class scientific organization," said Dr. Paya.  "Moreover, the maturing technologies and scientific platforms contributed by the founders of IDC have the potential to revolutionize how we treat and prevent the huge unmet medical need of chronic viral infections, cancer, and autoimmunity. Delivering these potential breakthrough therapies to patients worldwide is an exciting and unique opportunity."

Dr. Paya joins IDC from Elan Corporation, where he was President and led the Biotechnology commercial, marketing, clinical, research and development teams since 2008.  Dr. Paya joined Elan from Eli Lilly & Company, where he was Vice President, Lilly Research Laboratories, and Global Leader of the Diabetes and Endocrine Platform, responsible for the company's diabetes and endocrine franchise. Prior to his career at Lilly, Dr. Paya had a distinguished academic career at the Mayo Clinic where he was a tenured Professor of Medicine, Immunology and Pathology, and Vice Dean of the Clinical Investigation program.

About Immune Design Corp.

Immune Design Corp. is a privately held, clinical-stage biotechnology company based in Seattle, Washington and formed in 2008 to bring together some of the world's leaders in the field of molecular immunology to develop vaccines for the treatment and prevention of infectious and malignant disease. The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response. This goal is accomplished through the application of two proprietary technology platforms that activate the immune system by distinct mechanisms.

Additional information can be found on the company's website at www.immunedesign.com.

Contact Media:

Cassie Ostrander 206-826-7901 or media@immunedesign.com


'/>"/>
SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune to Present 11 Abstracts on Influenza at 45th Annual National Immunization Conference
2. Reportlinker Adds Therapeutics for Immune System Disorders
3. American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
4. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
5. MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
6. Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens
7. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
8. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
9. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
10. MedImmune Focused on Revolutionizing Cancer Care
11. London Genetics and Astrimmune to Collaborate on Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
(Date:2/11/2016)... Feb. 11, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the engagement of Lars E. ... Medical Consultant. Dr. Birgerson will provide strategic medical ... operations team to help ensure timely facilitation of ...
(Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Aytu ... on developing treatments for urological and related conditions, announced ... for the second fiscal quarter of 2016 on Tuesday, ... will review recent accomplishments and provide an overview of ... financial results for the quarter ended December 31, 2015. ...
Breaking Medicine Technology:
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):